Pharmacoeconomic Guidelines: Baltic (Latvia, Lithuania, Estonia)

Country/Region: Baltic (Latvia, Lithuania, Estonia)
PE Guidelines
Baltic guideline for economic evaluation of pharmaceuticals (Pharmacoeconomic Analysis) (2002)
PDF in English

Information current as of Tuesday, July 19, 2022

Key Features

Type of Guidelines PE Guidelines
Title and year of the document Baltic guideline for economic evaluation of pharmaceuticals (Pharmacoeconomic Analysis) (2002)
Affiliation of authors Experts from health authorities of the Baltic countries
Purpose of the document Drug reimbursement and other state funding decisions
Standard reporting format included No
Disclosure Yes
Target audience of funding/ author's interests Pharmaceutical companies. Baltic states’ health authority
Perspective Mainly health care perspective. If relevant, societal
Indication Approved one(s)
Target population Yes
Subgroup analysis Yes
Choice of comparator Most commonly used alternative or practice. Be justified.
Time horizon To model a sufficient analysis period when trial data provide too short a time frame
Assumptions required Not stated
Preferred analytical technique Any one of CMA, CEA, CUA. Need justification.
Costs to be included Only direct health care costs. If relevant, include all costs outside healthcare system, presented separately.
Source of costs Adapt local cost. Be specified.
Modeling Yes, requires details
Systematic review of evidences Encourage meta-analysis
Preference for effectiveness over efficacy Prefer data from RCTs
Preferred outcome measure Change in the health state. Absolute risk difference calculated
Preferred method to derive utility EuroQol, Health Utility Index
Equity issues stated Not stated
Discounting costs Yes, 5% justify for other rates
Discounting outcomes Yes, 5%
Sensitivity analysis-parameters and range Main assumption variables, confidence interval
Sensitivity analysis-methods Details of the statistical tests performed
Presenting results C/E ratio, ICER, total annual cost and benefit
Incremental analysis Yes
Total costs vs effectiveness (cost/effectiveness ratio) Yes
Portability of results (Generalizability) Adjustment needed
Financial impact analysis No
Mandatory or recommended or voluntary


Eglė Urbonavičiūtė, Chief Specialist, deputizing for the Head of Medical Technology Division, State Health Care Accreditation Agency (VASPVT), Vilnius, Lithuania and Diāna Arāja, Head, Pharmacy Division, Ministry of Health of the Republic of Latvia, Riga, Latvia
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now